We see that javascript is disabled or not supported by your browser - javascript is needed for important actions on the site. Read more

What's New - Home - Login

Member $avings: $81,998,792.62 | Books Available: 669,399 | Members Online: 156

Swap Used Books - Buy New Books at Great Prices!

How To Swap Books Sign Up Search submenu

PBS Market (New Books)

Gift Buying Guide

Book Browser Advanced Search Books Posted Today Member Book Reviews Award Winning Books NYT Best Sellers Amazon Best Sellers Most Traveled Copies Club Wish List

Discussion Forums Book Lists

Club Lists My Book Lists My Watched Lists Create a List

Blog Donations

School Donation Program In Memory of... Military Donation Program Friends of PBS

Box-O-Books Maps The Eclectic Pen Fun Stuff

20 Questions Sudoku Bookmark Creator

Top 100

Requests Posts Swappers Referrers Reviewers

Pulse of PBS Spread The Word

Invite Friends Bookmarks Facebook Page Facebook App More Ways...

Photo Gallery Recipes Club Tag Cloud Member Testimonials

Help Center submenu

How To Swap Books Browse Help Docs Ask the Librarian PBS Member Icons Live Help

Kiosk

PBS Market (New Books) Go Shopping Buy Credits Buy PBS Money Upgrade Membership Gift Certificates Transfer Credits

Need Help?

Search - Treatment of Atrial Fibrillation: Comparative Effectiveness Review Number 119

Treatment of Atrial Fibrillation Comparative Effectiveness Review Number 119
Author: U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality

Atrial fibrillation (AF) is a supraventricular tachyarrhythmia (any tachycardic rhythm originating above the ventricular tissue) and is characterized by uncoordinated atrial activation with consequent deterioration of mechanical function. Different systems have been proposed to classify AF. Although the type of AF can change over time, it is oft... more »en helpful to characterize it at a given moment, as this may guide treatment. Types of AF include first-detected, paroxysmal (arrhythmia terminates spontaneously within 7 days), persistent (arrhythmia is sustained beyond 7 days), longstanding persistent (usually lasting for more than 1 yr.), and permanent AF (in which cardioversion has failed or has not been attempted). The impact of AF is compounded by its known association with significant mortality, morbidity, and health care costs. Not only is the risk of death in patients with AF twice that of patients without AF, but AF can result in myocardial ischemia or even infarction, heart failure exacerbation, and tachycardia-induced cardiomyopathy if the ventricular rate is not well controlled. In some patients, AF can severely depreciate quality of life by causing shortness of breath, intractable fatigue, and near-syncope. However, the most dreaded complication of AF is thromboembolism, especially stroke. The risk of stroke in patients with AF is up to 8% per yr., depending on the presence of stroke risk factors. Importantly, when ischemic stroke occurs in patients with AF, it is either fatal or of moderate to high severity in the majority of patients. The management of AF and its complications is responsible for almost $16 billion in costs to the U.S. health care system each year. This review is designed to evaluate the comparative safety and effectiveness of a wide range of pharmacological and procedural rate- and rhythm-control strategies for the treatment of adult patients with paroxysmal, persistent, or permanent AF. The first three KQs focus on rate-control therapies: KQ1: What are the comparative safety and effectiveness of pharmacological agents used for ventricular rate control in patients with atrial fibrillation? Do the comparative safety and effectiveness of these therapies differ among specific patient subgroups of interest? KQ2: What are the comparative safety and effectiveness of a strict rate-control strategy versus a more lenient rate-control strategy in patients with atrial fibrillation? Do the comparative safety and effectiveness of these therapies differ among specific patient subgroups of interest? KQ3: What are the comparative safety and effectiveness of newer procedural and other nonpharmacological rate-control therapies compared with pharmacological agents in patients with atrial fibrillation for whom initial pharmacotherapy was ineffective? Do the comparative safety and effectiveness of these therapies differ among specific patient subgroups of interest? The next two KQs focus specifically on rhythm-control therapies: KQ4: What are the comparative safety and effectiveness of available antiarrhythmic agents and electrical cardioversion for conversion of atrial fibrillation to sinus rhythm? Do the comparative safety and effectiveness of these therapies differ among specific patient subgroups of interest? KQ5: What are the comparative safety and effectiveness of newer procedural rhythm-control therapies, other nonpharmacological rhythm-control therapies, and pharmacological agents for maintenance of sinus rhythm in atrial fibrillation patients? Do the comparative safety and effectiveness of these therapies differ among specific patient subgroups of interest? The final KQ seeks to evaluate the comparison of the available rate- and rhythm-control therapies: KQ6: What are the comparative safety and effectiveness of rate-control therapies versus rhythm-control therapies in patients with atrial fibrillation? Do the comparative safety and effectiveness of these therapies differ among specific patient subgroups of interest?

ISBN-13: 9781491256565
ISBN-10: 1491256567
Publication Date: 8/1/2013
Pages: 352
Rating:

0 stars, based on 0 rating

Publisher: CreateSpace Independent Publishing Platform
Book Type: Paperback
Members Wishing: 0
Reviews: Amazon | Write a Review

Genres:

Medical Books >> Research

Back to the Top ↑

Search - Treatment of Atrial Fibrillation: Comparative Effectiveness Review Number 119

Loading...